Combination therapy shows promise to treat a rare, catastrophic pediatric brain cancer
[ad_1] St. Jude Children’s Research Hospital scientists identified a promising combination approach to treat a rare, but catastrophic pediatric brain cancer called atypical teratoid rhabdoid tumor (ATRT). Reactivating and maintaining p53, a protein responsible for tumor suppression, using the drugs idasantulin and selinexor, respectively, was well-tolerated, reduced tumor burden and increased survival in a laboratory…
